PRAMIPEXOLE GxP pramipexole dihydrochloride 0.25 mg tablets blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

pramipexole dihydrochloride monohydrate

Forma farmaceutica:

Tablet, uncoated

Composizione:

Excipient Ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide

Via di somministrazione:

Oral

Confezione:

10, 30, 100

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.

Dettagli prodotto:

Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2014-09-23